HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead
HOOKIPA Pharma (NASDAQ:HOOK) on Wednesday said it had achieved a $5M milestone payment under its collaboration agreement with Gilead Sciences (GILD).
Shares of the micro-cap clinical-stage biopharmaÂ rose 3.8%Â to $0.83 in afternoon trade.
"HOOKIPA completed and delivered a regulatory support package for Gileadâs Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using HOOKIPAâs arenaviral platform," HOOK said in a statement.
The first participant in the early-stage trial is expected to be dosed in 2023.
The hepatitis B program is one of two development programs in HOOK's collaboration and license agreement with GILD.